Economic-epidemiological decision models to support malaria elimination in the Greater Mekong Sub-Region

• Drug & regimen: 3 monthly rounds of Dihydroartemisinin-piperaquine on days 1, 2 and 3, primaquine, low single dose
• The interventions accounted for in the model were: universal coverage of early diagnosis; treatment and long-lasting insecticidal nets via community health workers; three monthly rounds of mass drug administration targeted towards high prevalence villages, with the addition of three monthly doses of the RTS,S vaccine delivered en masse to the same high prevalence sub-population. A booster dose of vaccine was added 1 year later; screening and treatment of individuals entering the simulated population.
• Target & size population: Savannakhet province in Lao PDR was used to simulate the impact of the package of interventions and MDA and RTS,S were targeted to the higher prevalence villages
• Outcome measures: Prevalence and incidence by ultrasensitive quantitative PCR
• Time of follow-up: 24 months
• Results: In this modelling approach, the sequential introduction of interventions in an integrated strategy (universal access to early diagnosis and adequate treatment, improved access to insecticide-impregnated bed nets, three monthly rounds of MDA together with RTS,S vaccination followed by a booster dose of vaccine, and screening and treatment of imported cases) was predicted to be sufficient to stop malaria transmission from Savannakhet within a 3-year period. The addition of MDA is predicted to accelerate the reduction in prevalence and incidence to the levels predicted to be achievable with universal early diagnosis and adequate treatment and LLINs. Adding mass vaccination is predicted to interrupt transmission. 

Modelling

Bill & Melinda Gates Foundation, GrantsMalaria elimination transmission and costing in the Asia-Pacific: Developing an investment case

Drug-based Strategies
Modeling

Sep 2014 — Sep 2018

$2.58M

Asia, Southeastern
Lao PDR

Mass Drug Administration (MDA)